No Data
No Data
H.C. Wainwright Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Raises Target Price to $10
Express News | ProQR Therapeutics N.V. : H.c. Wainwright Raises Target Price to $10 From $5
Chardan Capital Maintains ProQR Therapeutics(PRQR.US) With Buy Rating, Announces Target Price $4
ProQR Therapeutics Shows Revenue Growth Amid Financial Challenges
ProQR Therapeutics Reports Q3 EPS (EUR 0.10) Vs. (EUR 0.07) Last Year
ProQR Therapeutics Sees Cash Runway Into Mid-2027
No Data
No Data
Stock_Drift OP Krystian 1983 : What’s down 30%?
Stock_Drift OP Krystian 1983 : Ask the market. I don’t control it, just report it.
Stock_Drift OP Krystian 1983 : Like a lot of them. $Maxeon Solar Technologies (MAXN.US)$ for example.
Krystian 1983 Stock_Drift OP : I Will try to report That thanks you
Stock_Drift OP Krystian 1983 : Sorry. The market does what it does, even the best DD doesn’t always produce.
View more comments...